期刊文献+

Vaginal Testosterone Propionate with Misoprostol Prior to Removal of Intrauterine Devices in Postmenopausal Women

Vaginal Testosterone Propionate with Misoprostol Prior to Removal of Intrauterine Devices in Postmenopausal Women
原文传递
导出
摘要 Objective To explore and investigate a new treatment of releasing the risks and pain in removing intrauterine devices (IUD) from postmenopausal women. Methods Totally 240 postmenopausal women who needed to remove IUD were randomly divided into 3 groups. Group A (n =80) were preoperatively treated with 20 g/L vaginal testosterone propionate cod liver oil ointment (1 g/d) over a 2-week span of period, and vaginal misoprostol (200 μg) was one-time used at 2-3 h before operation. Group B (n =80) were treated with oral estradiol valerate (3 mg/d) from 7 d before operation. Other 80 women (group C) were treated with vaginal cod liver oil ointment (1 g/d) over a 2-week span of period before the operation day. The degree of cervical relaxation, operational difficulty, blood loss volume, the length of operation time and visual analogue scales (VAS) were evaluated, also the serum estradiol, testosterone and endometrial thickness were measured before and after medication. Results The degree of cervical relaxation, operational difficulty, blood loss, the length of operation time and VAS in group A were significantly better than those group C (P〈0.01), whiles its blood loss volume was less than group B (P〈0.05) and there were no significant differences in serum estradiol, testosterone and endometrial thickness before and after medication. Conclusion Preoperative vaginal testosterone propionate combined with misoprostol would reduce the operational difficulties/risks and release the suffering of patients. The study may represent a safe and effective alternative to remove IUD in postmeno- pausal women. Objective To explore and investigate a new treatment of releasing the risks and pain in removing intrauterine devices (IUD) from postmenopausal women. Methods Totally 240 postmenopausal women who needed to remove IUD were randomly divided into 3 groups. Group A (n =80) were preoperatively treated with 20 g/L vaginal testosterone propionate cod liver oil ointment (1 g/d) over a 2-week span of period, and vaginal misoprostol (200 μg) was one-time used at 2-3 h before operation. Group B (n =80) were treated with oral estradiol valerate (3 mg/d) from 7 d before operation. Other 80 women (group C) were treated with vaginal cod liver oil ointment (1 g/d) over a 2-week span of period before the operation day. The degree of cervical relaxation, operational difficulty, blood loss volume, the length of operation time and visual analogue scales (VAS) were evaluated, also the serum estradiol, testosterone and endometrial thickness were measured before and after medication. Results The degree of cervical relaxation, operational difficulty, blood loss, the length of operation time and VAS in group A were significantly better than those group C (P〈0.01), whiles its blood loss volume was less than group B (P〈0.05) and there were no significant differences in serum estradiol, testosterone and endometrial thickness before and after medication. Conclusion Preoperative vaginal testosterone propionate combined with misoprostol would reduce the operational difficulties/risks and release the suffering of patients. The study may represent a safe and effective alternative to remove IUD in postmeno- pausal women.
出处 《Journal of Reproduction and Contraception》 CAS 2013年第4期229-236,共8页 生殖与避孕(英文版)
关键词 POSTMENOPAUSE intrauterine device (IUD) testosterone propionate MISOPROSTOL postmenopause intrauterine device (IUD) testosterone propionate misoprostol
  • 相关文献

参考文献15

  • 1Wu HY, Zeng XQ, Zhang XH, et al. Clinical observation of misoprostol and nilestriol for IUD removal hard cases in post-menopausal women. Chin J Fam Plan (in Chinese), 2007, 15(3): 175-6.
  • 2Luo CL. Clinical observation of oral progynova for IUD removal in post-menopausal women. Chin J Pract Med (in Chinese), 2006,19(6):112-3.
  • 3Kang L. Nilestriol combined with lidocaine administration for IUD removal in post-menopausal women. J Pract Gynaecol Obstet (in Chinese), 2000,16(2):110-1.
  • 4Hoilen PJ, Graila r J, Kris MG, et al. A comparison of visual analogue and numerical rating scale formats for the lung Cancer symptom scale (LCSS): does format affect patient ratings of symptoms and quality of life? Qual Life Res, 2005, 14(3):837-47.
  • 5Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician, 2000, 61 (10):3090-6.
  • 6Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004. lnt J Gynaecol Obstet, 2005, 88(2):222-8.
  • 7Judd HL, Judd GE, Lucas WE, et al. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab, 1974,39(6): 1 020-4.
  • 8Judd HL, Shamonki 1M, Frumar AM, et al. Origin of serum estradiol in postmenopausal women. Obstet Gynecol, 1982,59(6):680-5.
  • 9Leiblum S, Bachmann G, Kemmann E, et al. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA, 1983,249(16):2195-8.
  • 10Raghunandan C, Agrawal S, Dubey P, et al. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med, 2010,7(3):1284-90.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部